KR101907849B1 - Composition for preventing, improving or treating disorder associated with polycystic ovary syndrome comprising extract of Ecklonia cava as effective component - Google Patents
Composition for preventing, improving or treating disorder associated with polycystic ovary syndrome comprising extract of Ecklonia cava as effective component Download PDFInfo
- Publication number
- KR101907849B1 KR101907849B1 KR1020170048334A KR20170048334A KR101907849B1 KR 101907849 B1 KR101907849 B1 KR 101907849B1 KR 1020170048334 A KR1020170048334 A KR 1020170048334A KR 20170048334 A KR20170048334 A KR 20170048334A KR 101907849 B1 KR101907849 B1 KR 101907849B1
- Authority
- KR
- South Korea
- Prior art keywords
- polycystic ovary
- ovary syndrome
- extract
- preventing
- composition
- Prior art date
Links
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 71
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 239000000284 extract Substances 0.000 title claims description 48
- 241001512722 Ecklonia cava Species 0.000 title claims description 10
- 201000010099 disease Diseases 0.000 claims abstract description 29
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 claims abstract description 10
- 201000010066 hyperandrogenism Diseases 0.000 claims abstract description 10
- 206010036601 premature menopause Diseases 0.000 claims abstract description 10
- 231100000539 ovarian failure Toxicity 0.000 claims abstract description 8
- 201000000736 Amenorrhea Diseases 0.000 claims abstract description 7
- 206010001928 Amenorrhoea Diseases 0.000 claims abstract description 7
- 231100000540 amenorrhea Toxicity 0.000 claims abstract description 7
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 claims abstract description 6
- 206010027514 Metrorrhagia Diseases 0.000 claims abstract description 6
- 206010033165 Ovarian failure Diseases 0.000 claims abstract description 6
- 201000004535 ovarian dysfunction Diseases 0.000 claims abstract description 6
- 230000036541 health Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 235000013376 functional food Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 241001512723 Ecklonia Species 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- -1 ring Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010020765 hypersomnia Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract description 32
- 102000009151 Luteinizing Hormone Human genes 0.000 abstract description 22
- 108010073521 Luteinizing Hormone Proteins 0.000 abstract description 22
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract description 22
- 229940040129 luteinizing hormone Drugs 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 21
- 229940088597 hormone Drugs 0.000 abstract description 17
- 239000005556 hormone Substances 0.000 abstract description 17
- 239000003098 androgen Substances 0.000 abstract description 16
- 230000003325 follicular Effects 0.000 abstract description 16
- 230000004936 stimulating effect Effects 0.000 abstract description 16
- 229960003604 testosterone Drugs 0.000 abstract description 16
- 238000004519 manufacturing process Methods 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- 230000003247 decreasing effect Effects 0.000 abstract description 8
- 208000009774 Follicular Cyst Diseases 0.000 abstract description 7
- 229940018973 ecklonia cava extract Drugs 0.000 abstract description 4
- 201000002595 endometriosis of ovary Diseases 0.000 abstract description 2
- 208000000509 infertility Diseases 0.000 abstract description 2
- 231100000535 infertility Toxicity 0.000 abstract description 2
- 230000036512 infertility Effects 0.000 abstract description 2
- 208000030747 ovarian endometriosis Diseases 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 206010021033 Hypomenorrhoea Diseases 0.000 abstract 1
- 208000037093 Menstruation Disturbances Diseases 0.000 abstract 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 52
- 229960003881 letrozole Drugs 0.000 description 51
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 21
- 229960002847 prasterone Drugs 0.000 description 21
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 11
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 229940028334 follicle stimulating hormone Drugs 0.000 description 11
- 238000010171 animal model Methods 0.000 description 8
- 230000002611 ovarian Effects 0.000 description 8
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 231100000208 phytotoxic Toxicity 0.000 description 7
- 230000000885 phytotoxic effect Effects 0.000 description 7
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000009245 menopause Effects 0.000 description 6
- 229940041616 menthol Drugs 0.000 description 6
- 229960003105 metformin Drugs 0.000 description 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- 229960005095 pioglitazone Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 201000005670 Anovulation Diseases 0.000 description 3
- 206010002659 Anovulatory cycle Diseases 0.000 description 3
- 240000008397 Ganoderma lucidum Species 0.000 description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 231100000552 anovulation Toxicity 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000019994 cava Nutrition 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229920001339 phlorotannin Polymers 0.000 description 3
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 241001474374 Blennius Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- 206010017711 Gangrene Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000896517 Homo sapiens Steroid 17-alpha-hydroxylase/17,20 lyase Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102100021719 Steroid 17-alpha-hydroxylase/17,20 lyase Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000938 luteal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 208000025661 ovarian cyst Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000035175 Oligomenorrhea Diseases 0.000 description 1
- 206010030295 Oligomenorrhoea Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000233614 Phytophthora Species 0.000 description 1
- 231100000674 Phytotoxicity Toxicity 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000003250 oocyst Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000000624 ovulatory effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229930000184 phytotoxin Natural products 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 감태 추출물을 유효성분으로 포함하는 다낭성 난소 증후군 관련 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, ameliorating or treating a polycystic ovary syndrome-related disease comprising a gangrene extract as an active ingredient.
다낭성 난소 증후군은 가임 여성의 4~12%가 영향을 받고 있는 내분비대사 질환이다. 1990년 미국 국립보건원(National Institutes of Health)에서 제시한 다낭성 난소 증후군의 진단 기준은 만성 무배란 및 임상적 또는 생화학적 고안드로겐혈증의 두 가지 모두를 요구한다. 반면 2003년 개정된 유럽/미국 생식내분비학회 연합의 진단 기준은 만성 무배란, 임상적 또는 생화학적 고안드로겐혈증, 그리고 커진 난소의 가장자리를 따라 10여 개의 작은 난포가 염주모양을 하고 있는 양상의 세 가지 기준 중에서 두 가지 이상을 만족하는 경우에 다낭성 난소 증후군으로 정의하고 있다.Polycystic ovary syndrome is an endocrine metabolic disease in which 4-12% of women are affected. In 1990, the criteria for diagnosis of polycystic ovary syndrome presented by the National Institutes of Health required both chronic anovulation and clinical or biochemical hyperandrogenemia. On the other hand, the 2003 European / American Association for the Reproductive Endocrinology Society (FSEE) has three diagnostic criteria: chronic anovulation, clinical or biochemical hyperandrogenemia, and the appearance of 10 small follicles along the edge of the enlarged ovary Polycystic ovary syndrome is defined as two or more of the criteria.
아직 다낭성 난소 증후군의 발병 원인은 명확히 밝혀지지 않고 있다. 다른 복합성 질환들과 마찬가지로 다낭성 난소 증후군의 발병에도 유전적 인자 및 환경적 인자가 모두 작용하는 것으로 여겨진다. 연구의 기법이 발달해 가면서 일차적 병태 생리의 초점은 난소에서 시상하부-뇌하수체 축으로 옮겨갔고, 이후 인슐린 작용의 결함 쪽으로 옮겨가고 있는 추세이다. 다양한 유전학적 요인과 다낭성 난소 증후군의 연관성에 관한 연구 결과들이 보고되고 있지만, 아직까지 임상적으로 적용 가능한 유전학적 검사는 없는 상태이다.The cause of polycystic ovary syndrome has yet to be clarified. Like other complex diseases, the genetic and environmental factors are thought to be responsible for the onset of polycystic ovary syndrome. As the technique of the study develops, the focus of primary pathophysiology is shifting from the ovaries to the hypothalamic-pituitary axis, and then to the defects of insulin action. Although studies on the association of various genetic factors with polycystic ovary syndrome have been reported, there are no clinically applicable genetic tests yet.
다낭성 난소 증후군의 증상으로는 (1) 희발월경(oligomenorrhea)이나 무월경(amenorrhea), (2) 안드로겐과다혈증(hyperandrogenism) 및/또는 남성호르몬과다증 (hyperandrogenemia), (3) 형태학적인 다낭(polycystic ovary morphology)이다. 이외에도 나이와 몸무게를 대상으로 한 조사를 토대로 살펴보면 대조군과 비교해서 약 50%의 다낭성 난소 증후군 여성에게서 혈청 내 황체형성 호르몬의 과분비(luteinizing hormone(LH) hypersecretion), 인슐린 저항성(insulin resistance), 및 보상적 고인슐린혈증(compensatory hyperinsulinemia) 등의 생화학적 특징이 공통적으로 나타난다.Symptoms of polycystic ovary syndrome include (1) oligomenorrhea or amenorrhea, (2) androgen and hyperandrogenism and / or hyperandrogenemia, (3) polycystic ovary morphology )to be. In addition, a study of age and weight showed that the luteinizing hormone (LH) hypersecretion in serum, insulin resistance, and compensation were significantly lower in women with polycystic ovary syndrome (50% And biochemical features such as compensatory hyperinsulinemia are common.
다낭성 난소 증후군 관련 질환의 일례로, 난소 부전증(premature ovarian failure)은 난소기능이 정상적으로 작용하지 않는 경우에 발생하는 것으로서 배란성 주기 부정증(不整症), 황체 기능 부전증, 무배란성 주기 부정증으로 분류한다. 무배란성 주기증은 사춘기, 갱년기에서는 생리적으로도 나타나지만 성숙부인에서는 불임이 된다. 황체 기능 부전증은 황체 기능의 퇴행이 빨라, 불임과 유산의 원인이 된다. 배란성 주기 부정증은 주기의 길이에만 이상이기 때문에 난포기의 길이의 이상 때문으로 보고 있다. 이러한 난소 부전증은 기본적으로 연령이 많아져 폐경이 될 시기가 오면 폐경기 증상으로 나타날 수도 있지만 비정상적으로 40세 미만에서 이러한 증상이 나타나 임신에 어려움이 발생하기도 한다. 이러한 상태에서 증상이 더 악화되면 조기폐경으로 이어지게 된다.An example of polycystic ovary syndrome related diseases is premature ovarian failure, which occurs when the ovarian function is not functioning normally. It is classified as ovulatory cycle irregularity, luteal dysfunction, and anovulation cycle irregularity do. Anovulatory sex donation is physiologically present in puberty and menopausal age but becomes infertile in mature women. Lung dysfunction leads to rapid degeneration of the luteal function, causing infertility and abortion. The ovulation cycle irregularity is considered to be due to the abnormality of the length of the irregularity because it is more than the length of the cycle. This ovarian failure is basically an age-related increase in menopause symptoms may appear as a period of menopause, abnormally below 40 years of age, such symptoms may occur in pregnancy difficulties. If symptoms worsen in this condition, it leads to premature menopause.
또한, 난소 기능의 감소로 야기된 시상하부-뇌하수체-난소로 이어지는 성선 축의 기능 실조가 원인이 되고 이로 인하여 성호르몬, 지질 및 심혈관계 대사, 골대사, 기억 작용 등의 신체 및 정신적인 변화가 나타난다. 갱년기의 시작은 폐경과 더불어 시작되며 폐경기 여성은 호르몬 불균형과 칼슘 결핍 및 체내 산화적 스트레스 증가로 여러 질병의 위험에 처하게 된다. 즉, 폐경기의 에스트로겐 변화로 관상동맥 질환, 골다공증, 알츠하이머 등 질환의 발병률은 급증하게 되고, 특히 폐경기 이후 에스트로겐 감소는 급속한 골 손실을 초래하게 된다.In addition, it is caused by dysfunction of the gonadal axis leading to hypothalamus-pituitary-ovary caused by a decrease in ovarian function, which causes physical and mental changes such as sex hormone, lipid and cardiovascular metabolism, bone metabolism, and memory function. The onset of menopause begins with menopause, and menopausal women are at risk for many diseases due to hormone imbalance, calcium deficiency and increased oxidative stress in the body. In other words, estrogen change in menopause causes the incidence of diseases such as coronary artery disease, osteoporosis, and Alzheimer to increase rapidly, especially after menopause, estrogen reduction causes rapid bone loss.
한편, 감태는 미역과에 속하는 해조류로서 우리나라 동해 남부와 제주도를 포함한 남해안 일대에 서식한다. 감태에는 바다식물의 폴리페놀(polyphenol)이라는 플로로타닌(phlorotannin)이 많이 함유되어 있다. 특히 최근 노화를 비롯한 여러 가지 성인병의 원인이 free-radical에 의한 산화임이 밝혀지면서, 플로로타닌(phlorotannin)과 같은 강한 항산화 활성 물질을 다량 함유한 감태가 새로운 기능성 소재로서 주목을 받고 있다. 감태에는 플로로타닌(phlorotannin) 외에도 알파-토코페롤과 같은 항산화물질도 함유되어있다. 감태의 생리활성 성분과 이의 이용에 대한 연구가 진행되고 있다. 김진아, 이종미 등은 연구 논문 (Kim et al., Food Sci. Biotechnol. 2004. Vol 13, 페이지 476-480)에 감태 phlorotannin의 항산화 활성과 미백효과 등에 대하여 개시하고 있고, 또 다른 연구논문 (김진아 등. 대한가정학회지, 2004. Vol. 42. No. 5, 페이지 193-203)에 열처리 또는 추출 방법에 의한 항산화효능 효과에 대한 연구도 보고된 바 있다.On the other hand, it is a seaweed belonging to the seaweed family, and it lives in the southern part of Korea including the southern part of the East Sea and Jeju Island. Phytophthora contains a lot of phlorotannin called polyphenol of sea plant. Recently, it has been found that free radical oxidative causes of various adult diseases including aging, and phytotoxicity, which contains a large amount of strong antioxidant substances such as phlorotannin, are attracting attention as a new functional material. In addition to phlorotannin, it also contains antioxidants such as alpha-tocopherol. Studies on physiologically active components of menthol and their use have been under way. (Kim et al., Food Sci. Biotechnol., 2004, Vol. 13, pp. 476-480) disclose the antioxidant activity and whitening effect of phterotannin, , 2004. Vol. 42, No. 5, pp. 193-203) have also been reported on the antioxidant efficacy effects by heat treatment or extraction methods.
본 발명의 감태 추출물의 의약 용도에 관한 종래기술로는 한국공개특허 제2013-0028261호에 감태 추출물을 유효성분으로 함유하는 파킨슨 질환의 예방 또는 치료용 조성물에 관한 기술이 알려져 있으나, 본 발명의 감태 추출물을 유효성분으로 포함하는 다낭성 난소 증후군 관련 질환의 예방, 개선 또는 치료용 조성물에 대해서는 알려진 바 없다.As a conventional technology related to the use of the phytotoxic extract of the present invention, Korean Patent Laid-Open Publication No. 2013-0028261 discloses a composition for preventing or treating Parkinson's disease, which contains a phytate extract as an active ingredient, There is no known composition for preventing, ameliorating or treating polycystic ovary syndrome-related diseases containing an extract as an active ingredient.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명은 감태 추출물을 유효성분으로 포함하는 다낭성 난소 증후군 관련 질환의 예방, 개선 또는 치료용 조성물을 제공하고, 본 발명의 유효성분인 감태 추출물은 안드로겐 DHEA(Dehydroepiandrosterone)의 생성 조절 활성이 있으며, 혈중 황체형성호르몬(luteinizing hormone)/난포자극호르몬 비율 감소 효과, 혈중 난포자극호르몬(follicular stimulating hormone) 증가 효과, 혈중 테스토스테론(testosterone) 및 난소 내 난포낭(follicular cyst) 수 감소 효과가 있다는 것을 확인함으로써, 본 발명을 완성하였다.The present invention provides a composition for preventing, ameliorating or treating polycystic ovary syndrome-related diseases, comprising a gangsia extract as an active ingredient. The gangsia extract, which is an active ingredient of the present invention, It has activity to regulate the production of androgen DHEA (Dehydroepiandrosterone), and has the effect of reducing the ratio of luteinizing hormone / follicle stimulating hormone, increasing follicular stimulating hormone, blood testosterone and ovarian cyst confirming that there is an effect of reducing the number of follicular cysts.
상기 목적을 달성하기 위하여, 본 발명은 감태(Ecklonia cava) 추출물을 유효성분으로 포함하는 다낭성난소 증후군(polycystic ovary syndrome) 관련 질환의 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating polycystic ovary syndrome-related diseases comprising Ecklonia cava extract as an active ingredient.
또한, 본 발명은 감태(Ecklonia cava) 추출물을 유효성분으로 포함하는 다낭성난소 증후군(polycystic ovary syndrome) 관련 질환의 예방 또는 개선용 건강기능식품 조성물을 제공한다.The invention also Ecklonia cava (Ecklonia The present invention provides a health functional food composition for preventing or ameliorating a polycystic ovary syndrome-related disease comprising an extract of cava as an active ingredient.
본 발명은 감태 추출물을 유효성분으로 포함하는 다낭성 난소 증후군 관련 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다. 본 발명의 유효성분인 감태 추출물은 안드로겐 DHEA(Dehydroepiandrosterone)의 생성 조절 활성이 있으며, 혈중 황체형성호르몬/난포자극호르몬 비율 감소 효과, 혈중 난포자극호르몬(follicular stimulating hormone) 증가 효과, 혈중 테스토스테론(testosterone) 및 난소 내 난포낭(follicular cyst) 수 감소 효과가 있으므로, 다낭성 난소 증후군 관련 질환인 고안드로겐 혈증, 무월경, 과소월경, 기능 이상성 자궁출혈, 조기폐경, 난임, 난소부전 및 자궁내막증 등의 관련 의약 또는 건강기능식품 산업에 널리 활용될 수 있다. The present invention relates to a composition for preventing, ameliorating or treating a polycystic ovary syndrome-related disease comprising a gangrene extract as an active ingredient. The phytotoxic extract of the present invention has an activity of regulating the production of androgen DHEA (Dehydroepiandrosterone), and has an effect of reducing the ratio of the luteinizing hormone / follicle stimulating hormone in the blood, the effect of increasing the follicular stimulating hormone in the blood, the testosterone in the blood, And ovarian follicular cysts. Therefore, the present invention relates to a pharmaceutical composition for the treatment of polycystic ovary syndrome related diseases such as hyperandrogenemia, amenorrhea, hypometasia, dysfunctional uterine bleeding, premature menopause, ovarian failure, ovarian failure and endometriosis, It can be widely used in health functional foods industry.
도 1은 인간 부신 세포주(H295R)을 이용한 본 발명에 따른 감태 물 추출물(감태 H)의 안드로겐 DHEA(Dehydroepiandrosterone) 생성 조절 효과를 확인한 결과이다. Con은 대조군로서, 아무것도 처리하지 않은 세포이고, FOR은 안드로겐의 과다 분비를 유도하기 위해 10μM의 포스콜린(Forskolin)을 처리한 세포군이며, MET는 1mM의 메트포르민(metformin)을 처리한 양성대조군의 세포이고, PIO는 10μM의 피오글리타존(pioglitazone)을 처리한 양성대조군의 세포이다. ***은 Con에 비해 포스콜린을 처리한 세포에서 안드로겐 DHEA 생성이 통계적으로 유의미하게 증가하였다는 것으로, p<0.001임을 의미하며, ##는 포스콜린 처리에 의해 증가된 안드로겐 DHEA가 본 발명의 감태 추출물의 처리에 의해 통계적으로 유의미하게 감소하였다는 것으로, p<0.01이다.
도 2는 본 발명의 감태 추출물의 인간 부신 세포주(H295R)을 이용한 안드로겐 DHEA(Dehydroepiandrosterone)의 생성에 관여하는 단백질의 발현량을 웨스턴 블랏으로 확인한 결과이다.
도 3은 본 발명에 따른 감태 추출물을 PCOS 동물모델에 투여하여, 혈중 황체형성호르몬/난포자극호르몬 비율의 감소 효과를 확인한 것이다. CON은 음성 대조군으로서 정상군이며, PCOS는 레트로졸(letrozole)을 투여하여 황체형성호르몬/난포자극호르몬 비율을 비정상적으로 증가시킨 PCOS군이며, PCOS+EC500은 레트로졸(letrozole) 및 감태 추출물의 투여군이고, PCOS+positive는 총 실험기간 4주 중, 전반부 2주 동안 1mg/kg/BW 레트로졸(letrozole) 투여 및 0.1mg/kg/BW 서방형 제형 삽입하고, 후반부 2주 동안은 레트로졸(letrozole)의 투여를 제외한 자연회복군으로 양성대조군이다. *은 CON에 비해 레트로졸(letrozole)을 투여한 군에서 혈중 황체형성호르몬/난포자극호르몬 비율이 통계적으로 유의미하게 증가하였다는 것으로, p<0.05임을 의미하며; #은 레트로졸(letrozole) 투여군 대비 레트로졸(letrozole) 및 감태 추출물의 투여군, 또는 레트로졸(letrozole) 처치 후 자연회복군의 혈중 황체형성호르몬/난포자극호르몬 비율이 통계적으로 유의미하게 감소하였다는 것으로, #는 p<0.05이다.
도 4는 본 발명에 따른 감태 추출물을 PCOS 동물모델에 투여하여, 난포자극호르몬(follicular stimulating hormone)의 증가를 확인한 것이다. CON은 음성대조군으로서 정상군이며, PCOS는 레트로졸(letrozole)을 투여하여 난포자극호르몬(follicular stimulating hormone)을 비정상적으로 감소시킨 PCOS군이며, PCOS+EC500은 레트로졸(letrozole) 및 감태 추출물의 투여군이고, PCOS+positive는 총 실험기간 4주 중, 전반부 2주 동안 1mg/kg/BW 레트로졸(letrozole) 투여 및 0.1mg/kg/BW 서방형 제형 삽입하고, 후반부 2주 동안은 레트로졸(letrozole)의 투여를 제외한 자연회복군으로 양성대조군이다. *은 CON에 비해 레트로졸(letrozole)을 투여한 군에서 난포자극호르몬(follicular stimulating hormone)이 통계적으로 유의미하게 감소하였다는 것으로, p<0.05임을 의미하며, #은 레트로졸(letrozole) 투여군 대비 레트로졸(letrozole) 및 본 발명의 감태 추출물의 투여군 또는 레트로졸(letrozole) 처치 후 자연회복군의 난포자극호르몬(follicular stimulating hormone)이 통계적으로 유의미하게 증가하였다는 것으로, #는 p<0.05이다.
도 5는 본 발명에 따른 감태 추출물을 PCOS 동물모델에 투여하여, 테스트스테론(testosterone) 감소 효과를 확인한 것이다. CON은 음성대조군으로서 정상군이며, PCOS는 레트로졸(letrozole)을 투여하여 테스트스테론(testosterone)을 비정상적으로 증가시킨 PCOS군이며, PCOS+EC500은 레트로졸(letrozole) 및 감태 추출물의 투여군이고, PCOS+positive는 총 실험기간 4주 중, 전반부 2주 동안 1mg/kg/BW 레트로졸(letrozole) 투여 및 0.1mg/kg/BW 서방형 제형 삽입하고, 후반부 2주 동안은 레트로졸(letrozole)의 투여를 제외한 자연회복군으로 양성대조군이다. *은 CON에 비해 레트로졸(letrozole)을 투여한 군에서 테스트스테론(testosterone)이 통계적으로 유의미하게 증가하였다는 것으로, p<0.05임을 의미하며, #은 레트로졸(letrozole) 투여군 대비 레트로졸(letrozole) 및 본 발명의 감태 추출물의 투여군 또는 레트로졸(letrozole) 처치 후 자연회복군의 테스트스테론(testosterone)이 통계적으로 유의미하게 감소하였다는 것으로, #는 p<0.05이다. FIG. 1 shows the results of confirming the effect of controlling the production of androgen DHEA (Dehydroepiandrosterone) by the extract of Liliaceae according to the present invention using human adrenal gland cell line (H295R). Con is a control group, the cells are untreated, FOR is a group of cells treated with 10 μM of Forskolin to induce an over secretion of androgens, MET is a group of positive control cells treated with 1 mM metformin And PIO is a positive control cell treated with 10 [mu] M pioglitazone. *** indicates that the production of androgen DHEA increased significantly in the cells treated with phosholin compared to Con, which means that p < 0.001, and that ## and < RTI ID = 0.0 > androgen < / RTI > It was statistically significantly decreased by the treatment of Ganoderma lucidum extract, p <0.01.
FIG. 2 shows the results of Western blot analysis of the expression levels of proteins involved in the production of androgen DHEA (Dehydroepiandrosterone) using the human adrenal gland cell line (H295R) of the menthol extract of the present invention.
FIG. 3 is a graph showing the effect of reducing the luteinizing hormone / follicle stimulating hormone ratio in the PCOS animal model by administering the phytotoxic extract according to the present invention. CON is a normal control group, PCOS is a PCOS group that abnormally increases luteinizing hormone / follicle stimulating hormone ratio by administration of letrozole, PCOS + EC500 is a group of administration of letrozole and phytoextract Kg / BW letrozole and 0.1 mg / kg / BW sustained-release formulation for 2 weeks in the first half of the 4 weeks of the total experimental period, and letrozole (2 mg / kg / ), And it is a positive control group. * Means that the plasma luteinizing hormone / follicle stimulating hormone ratio was significantly increased in letrozole-administered group compared to CON, which means p <0.05;# Showed statistically significant decrease in the ratio of luteinizing hormone / follicle stimulating hormone in the natural recovery group after treatment with letrozole and gentle extract versus letrozole treatment compared to letrozole administration group , # Is p < 0.05.
FIG. 4 is a graph showing the increase in follicular stimulating hormone administered to the PCOS animal model according to the present invention. CON is a normal control group, PCOS is a PCOS group in which follicular stimulating hormone is abnormally reduced by administration of letrozole, PCOS + EC500 is a group of administration of letrozole and phytotoxin Kg / BW letrozole and 0.1 mg / kg / BW sustained-release formulation for 2 weeks in the first half of the 4 weeks of the total experimental period, and letrozole (2 mg / kg / ), And it is a positive control group. * Indicates a statistically significant decrease in follicular stimulating hormone in the letrozole group compared to CON, p <0.05, and # indicates that the dose of letrozole The statistically significant increase in the follicular stimulating hormone of the natural recovery group after administration of the letrozole and the phytotoxic extract of the present invention or the administration of letrozole was # <p <0.05.
FIG. 5 is a graph showing the effect of reducing the testosterone by administering the phytotoxic extract according to the present invention to an animal model of PCOS. CON is a normal group as a negative control, PCOS is a PCOS group in which testosterone is abnormally increased by administration of letrozole, PCOS + EC500 is a group of administration of letrozole and phytotoxic extract, PCOS + positive was injected with 1 mg / kg / BW letrozole and 0.1 mg / kg / BW sustained-release formulation for 2 weeks in the first 4 weeks of the total experimental period, and letrozole The group was a natural control group except for administration. * Indicates a statistically significant increase in testosterone in letrozole versus CON (p <0.05), while # indicates that letrozole versus letrozole letrozole) and the testosterone of the natural recovery group after administration of the extracts of the present invention or letrozole were statistically significantly decreased.
본 발명은 감태(Ecklonia cava) 추출물을 유효성분으로 포함하는 다낭성 난소 증후군(polycystic ovary syndrome) 관련 질환의 예방 또는 치료용 약학 조성물에 관한 것이다. The present invention is based on the finding that Ecklonia The present invention also relates to a pharmaceutical composition for preventing or treating polycystic ovary syndrome-related diseases comprising an extract of cava as an active ingredient.
상기 감태 추출물은 하기의 단계를 포함하는 방법에 의해 제조할 수 있으나, 이에 한정하지 않는다:The guttate extract may be prepared by a method including, but not limited to, the following steps:
(1) 감태에 추출용매를 가하여 추출하는 단계;(1) extracting an extractant with an extractant;
(2) 단계 (1)의 추출물을 여과하는 단계; 및 (2) filtering the extract of step (1); And
(3) 단계 (2)의 여과한 추출물을 농축하고 건조하여 추출물을 제조하는 단계. (3) concentrating the filtered extract of step (2) and drying to produce an extract.
상기 단계 (1)에서 추출용매는 물, C1~C4의 저급 알코올 또는 이들의 혼합물 중에서 선택하는 것이 바람직하며, 더 바람직하게는 물이지만 이에 한정하지 않는다.In the step (1), the extraction solvent is preferably selected from water, a C 1 -C 4 lower alcohol or a mixture thereof, more preferably water, but it is not limited thereto.
상기 제조방법에 있어서, 추출방법은 여과법, 열수 추출, 침지 추출, 환류 냉각 추출 및 초음파 추출 등의 당 업계에 공지된 모든 통상적인 방법을 이용할 수 있다. 상기 추출용매는 건조된 감태 중량의 1~20배 첨가하여 추출하는 것이 바람직하며, 더 바람직하게는 5~15배 첨가하는 것이고, 더욱더 바람직하게는 10배 첨가하는 것이다. 추출온도는 60~100℃인 것이 바람직하나 이에 한정하지 않는다. 또한, 추출시간은 1~48시간인 것이 바람직하며, 1~24시간이 더욱 바람직하고, 3시간이 가장 바람직하나 이에 한정하지 않는다. 상기 방법에 있어서, 단계 (3)의 농축은 진공 회전 농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정하지 않는다. 또한, 건조는 감압건조, 진공건조, 비등건조, 분무 건조 또는 동결건조하는 것이 바람직하며, 더 바람직하게는 동결건조이나 이에 한정하지 않는다.In the above production method, any conventional method known in the art such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction may be used. The extraction solvent is preferably added by 1 to 20 times, more preferably 5 to 15 times, and even more preferably 10 times by weight of the dried gut weight. The extraction temperature is preferably 60 to 100 DEG C, but is not limited thereto. The extraction time is preferably 1 to 48 hours, more preferably 1 to 24 hours, most preferably 3 hours. In the above method, the concentration of the step (3) is preferably, but not limited to, using a vacuum rotary condenser or a vacuum rotary evaporator. In addition, drying is preferably carried out under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, more preferably freeze drying or the like.
상기 다낭성 난소 증후군은 난소부전에 의한 것이 특징이며, 상기 다낭성 난소 증후군 관련 질환은 고안드로겐 혈증, 무월경, 과소월경, 기능 이상성 자궁출혈, 조기폐경, 난임 및 자궁내막증 중에서 선택된 하나 이상인 것이 바람직하지만 이에 한정하는 것은 아니다.The polycystic ovary syndrome is characterized by ovarian failure, and the polycystic ovary syndrome-related disease is preferably one or more selected from hyperandrogenemia, amenorrhea, hypometasia, dysfunctional uterine bleeding, premature menopause, fever and endometriosis. It does not.
상기 감태 추출물 이외에 추가로 약제학적으로 허용가능한 담체, 부형제 또는 희석제를 더 포함할 수 있다. In addition to the ghatti extract, a further pharmaceutically acceptable carrier, excipient or diluent may be further included.
본 발명의 약학 조성물은 경구 또는 비경구로 투여될 수 있으며, 비경구 투여 시 피부 외용 또는 복강 내, 직장, 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사 방식을 선택하는 것이 바람직하며, 가장 바람직하게는 피부 외용으로 사용한다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and it is preferable to select the intraperitoneal, rectal, rectal, intravenous, intramuscular, subcutaneous, intrauterine or intracerebral injection methods during parenteral administration, It is preferably used for external skin application.
본 발명의 약학 조성물은 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성 용제 및 현탁 용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 61, 카카오지, 라우린지, 글리세로 젤라틴 등이 사용될 수 있다.The pharmaceutical composition of the present invention can be prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like can be used.
본 발명에 따른 조성물은 약제학적으로 유효한 양으로 투여한다. 본 발명에 있어서, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여 부작용없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.
본 발명의 조성물의 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설률 및 질환의 중증도에 따라 그 범위가 다양하게 사용할 수 있다.The dosage of the composition of the present invention may be varied depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of disease.
또한, 본 발명은 감태(Ecklonia cava) 추출물을 유효성분으로 포함하는 다낭성난소 증후군(polycystic ovary syndrome) 관련 질환의 예방 또는 개선용 건강기능식품 조성물에 관한 것이다. The invention also Ecklonia cava (Ecklonia The present invention relates to a health functional food composition for preventing or ameliorating a polycystic ovary syndrome-related disease comprising an extract of cava as an active ingredient.
상기 다낭성 난소 증후군은 난소부전에 의한 것이 특징이며, 상기 다낭성 난소 증후군 관련 질환은 고안드로겐 혈증, 무월경, 과소월경, 기능 이상성 자궁출혈, 조기폐경, 난임 및 자궁내막증 중에서 선택된 하나 이상인 것이 바람직하지만 이에 한정하는 것은 아니다.The polycystic ovary syndrome is characterized by ovarian failure, and the polycystic ovary syndrome-related disease is preferably one or more selected from hyperandrogenemia, amenorrhea, hypometasia, dysfunctional uterine bleeding, premature menopause, fever and endometriosis. It does not.
상기 감태 추출물을 유효성분으로 포함하는 난소 부전증 관련 질환의 예방 또는 개선용 건강기능식품 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나로 제조하거나, 식품의 성분으로 첨가하여 제조될 수 있으며, 통상적인 방법에 따라 적절하게 제조될 수 있다. The health functional food composition for preventing or ameliorating ovarian failure-related diseases containing the menthol extract as an active ingredient may be prepared from any one selected from powders, granules, rings, tablets, capsules, candies, syrups and beverages, And can be suitably produced according to a conventional method.
본 발명의 감태 추출물을 첨가할 수 있는 식품의 일례로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 중에서 선택된 어느 하나의 형태일 수 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다.Examples of foods to which the menthol extract of the present invention can be added include meat products, sausages, breads, chocolate, candies, snacks, confectionery, pizza, ramen noodles, other noodles, dairy products including ice- A tea, a drink, an alcoholic beverage, and a vitamin complex, all of which include health functional foods in a conventional sense.
상기 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 및 천연 풍미제, 착색제 및 증진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알킨산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. The health functional foods include various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, alkynic acid and its salts, , pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices and vegetable drinks. These components may be used independently or in combination.
본 발명의 건강기능식품 조성물은 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.
The health functional food composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient. The natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.
[시료 및 실험방법] [Samples and Experimental Methods]
1. 시료1. Sample
본 발명의 일 실시예에서 사용하는 감태는 제주도에서 채취 또는 유통되는 감태를 구입하여 사용하였다.
The senses used in one embodiment of the present invention were purchased and used in Jeju Island.
1. 안드로겐 DHEA(Dehydroepiandrosterone) 생성량의 조절1. Control of Androgen DHEA (Dehydroepiandrosterone) Production
본 발명의 일 실시예에서는 인간 부신 세포주(H295R)에 10μM의 포스콜린(Forskolin)을 처리하여 안드로겐 DHEA(Dehydroepiandrosterone) 생성량을 증가시키고, 증가된 안드로겐 DHEA의 양을 감소시키는지 여부를 확인하기 위하여, 50㎍/㎖의 감태 물 추출물을 처리하였으며, 1mM의 메트포르민(metformin, MET) 및 10μM의 피오글리타존(pioglitazone, PIO)을 양성대조군으로 사용하였다.In one embodiment of the present invention, in order to confirm whether or not the human adrenal gland cell line (H295R) is treated with 10 μM Forskolin to increase the production of androgen DHEA (Dehydroepiandrosterone) and reduce the amount of increased androgen DHEA, 50 μg / ml of the extract was treated with 1 mM of metformin (MET) and 10 μM of pioglitazone (PIO) as a positive control.
한편, 상기 물질들을 처리한 부신 세포주(H295R)에서의 CYP17A1, p-CREB 단백질의 발현 정도를 웨스턴 블랏으로 확인하였다(도 2).
On the other hand, the expression level of CYP17A1 and p-CREB proteins in the adrenal cell line (H295R) treated with the above substances was confirmed by Western blot (Fig. 2).
2. 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio), 혈중 난포자극호르몬(follicular stimulating hormone), 혈중 테스토스테론(testosterone), 및 난소 내 난포낭(follicular cyst) 수의 변화 확인2. Changes in serum luteinizing hormone / follicle stimulating hormone ratio (LH / FSH ratio), follicular stimulating hormone, blood testosterone, and ovarian follicular cyst
실험동물로 사용된 암컷 SD 랫트는 ㈜오리엔트바이오에서 공급받아 사용하였다. 실험동물은 충남대학교 수의과대학의 공동동물실험실 사육시설에서 7일 동안 적응시킨 후 사용하였다.Female SD rats used as experimental animals were supplied from Orient Bio Co., Ltd. and used. The experimental animals were adapted for 7 days in the cooperative animal laboratory of Chungnam National University College of Veterinary Medicine.
실험방법은 충남대학교 동물실험윤리위원회의 심의를 거쳤으며, 실험동물 사육 및 유지는 충남대학교 공동동물실험실의 동물 관리 및 사용 규정에 입각하여 온도 23±1℃, 습도 50±10% 내외, 12시간 명암주기로 일정하게 유지된 사육실에서 IVC(individually ventilated cage)에 2마리씩 넣어 사육하였다.Experimental methods were reviewed by Chungnam National University Animal Experimental Ethics Committee. Breeding and maintenance of experimental animals were carried out at 23 ± 1 ℃, 50 ± 10% humidity, 12 hours Two rabbits were placed in an IVC (individually ventilated cage) in a constantly maintained incubation period with a light and dark cycle.
본 발명의 감태 추출물이 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio), 혈중 난포자극호르몬(follicular stimulating hormone), 혈중 테스토스테론(testosterone), 및 난소 내 난포낭(follicular cyst) 수 변화에 대한 효과를 조사하였다. 1mg/kg/BW 레트로졸(letrozole)과 0.1mg/kg/BW 레트로졸 SR 펠릿이 혼합된 실험군(PCOS)과 1mg/kg/BW 레트로졸(letrozole)과 0.1mg/kg/BW 레트로졸 SR 펠릿과 500mg/kg/BW 감태(Ecklonia cava) 추출물이 혼합된 실험군(PCOS+EC500)과 총 실험기간 4주 중, 전반부 2주 동안 1mg/kg/BW 레트로졸(letrozole) 투여 및 0.1mg/kg/BW 서방형 제형 삽입하고, 후반부 2주 동안은 레트로졸(letrozole)의 투여를 제외한 자연회복군(PCOS+positive)을 사용하여 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio), 혈중 난포자극호르몬(follicular stimulating hormone), 혈중 테스토스테론(testosterone), 및 난소 내 난포낭(follicular cyst) 수 활성 변화를 조사하였다.
The phytotoxic extracts of the present invention showed a significant effect on the ratio of the luteinizing hormone / follicle stimulating hormone (LH / FSH ratio), follicular stimulating hormone, blood testosterone, and ovarian follicular cyst . (PCOS) mixed with 1 mg / kg / BW letrozole and 0.1 mg / kg / BW letrozole SR pellets and 1 mg / kg / BW letrozole and 0.1 mg / kg / And 500 mg / kg / BW tendency ( Ecklonia cava) extract is mixed with the experimental group (PCOS + EC500) and a total test period of 4 weeks, the first part 2 weeks 1mg / kg / BW letrozole (letrozole) administration, and 0.1mg / kg / BW sustained release dosage form insert, and the second half 2 (LH / FSH ratio), follicular stimulating hormone (follicular stimulating hormone), and blood luteinizing hormone (FSH) ratio were measured using the natural recovery group (PCOS + positive) except for administration of letrozole Testosterone, and ovarian follicular cyst.
실시예Example 1. One. 감태Moth 추출물의 제조 Preparation of extract
건조한 감태 시료양에 대하여 10~15배의 100%(v/v) 물을 첨가하고, 100℃에서 3시간 환류추출하여 감태 추출액을 수득하였다. 상기 수득한 감태 추출액을 0.4㎛ 필터로 감압여과한 후, 진공회전농축기로 농축하여 동결건조기를 이용하여 동결건조하였다.
10 to 15 times of 100% (v / v) water was added to the dried chewing gum, and the mixture was refluxed at 100 ° C for 3 hours to obtain a chew extract. The obtained gentle extract solution was filtered under reduced pressure with a 0.4 mu m filter, concentrated by a vacuum rotary condenser, and lyophilized using a freeze dryer.
실시예Example 2. 2. 감태Moth 추출물의 안드로겐 DHEA( Extract of androgen DHEA ( dehydroepiandrosteronedehydroepiandrosterone )의 함량 조절 효과 확인),
50㎍/㎖의 감태 추출물을 인간 부신 세포주(H295R)에 처리한 결과, 도 1에 나타난 바와 같이, 안드로겐 DHEA(dehydroepiandrosterone) 생성이 유의미한 농도로 억제되는 것을 확인할 수 있었다. 1mM 메트포르민을 처리한 군에서도 감태 추출물과 유사한 안드로겐 DHEA(Dehydroepiandrosterone) 생성 조절 효과를 나타냈으나, 메트포르민의 경우 다낭성 난소 증후군 환자에게 인슐린 저항성을 낮추고 혈당을 조절하기 위해 사용되는 물질이나, 난소 기능 저하 현상을 유발할 수 있다고도 알려져 있다.As shown in FIG. 1, it was confirmed that the production of androgen DHEA (dehydroepiandrosterone) was inhibited to a significant concentration by treatment with a human adrenal cell line (H295R) at a dose of 50 占 퐂 / ml. In the group treated with 1 mM metformin, similar effects were observed for the production of androgen DHEA (Dehydroepiandrosterone), which is similar to that of the menthol extract. Metformin is a substance used for controlling insulin resistance and controlling blood glucose in patients with polycystic ovary syndrome, And the like.
한편, 본 발명의 감태 추출물을 처리한 세포에서 안드로겐 DHEA 함량을 조절하는 것으로 알려진 단백질인 CYP17A1 및 p-CREB 단백질의 함량이 감소한 것을 확인하였다(도 2).
Meanwhile, it was confirmed that the contents of CYP17A1 and p-CREB proteins, which are proteins known to regulate the androgen DHEA content in the cells treated with the menthol extract of the present invention, decreased (FIG. 2).
실시예Example 3. 3. 감태Moth 추출물의 혈중 황체형성호르몬/난포자극호르몬 비율( Blood luteinizing hormone / follicle stimulating hormone ratio of extract ( LHLH // FSHFSH ratio) 변화 확인 ratio change confirmation
1mg/kg/BW 레트로졸(letrozole)과 0.1mg/kg/BW 레트로졸 SR 펠릿이 혼합된 실험군(PCOS)과 1mg/kg/BW 레트로졸(letrozole)과 0.1mg/kg/BW 레트로졸 SR 펠릿과 500mg/kg/BW 감태 추출물(Ecklonia cava)이 혼합된 실험군(PCOS+EC500)과 총 실험기간 4주 중, 전반부 2주 동안 1mg/kg/BW 레트로졸(letrozole) 투여 및 0.1mg/kg/BW 서방형 제형 삽입하고, 후반부 2주 동안은 레트로졸(letrozole)의 투여를 제외한 자연회복군(PCOS+positive)을 사용하여 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio) 변화를 확인한 결과, 도 3에 개시한 바와 같이, PCOS 유도된 1mg/kg/BW 레트로졸(letrozole)의 투여군(PCOS)에서는 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio)이 통계적으로 유의미하게 증가하였고, 본 발명의 500mg/kg/BW 감태(Ecklonia cava) 추출물이 혼합된 실험군(PCOS+EC500)과 0.1mg/kg/BW 레트로졸(letrozole) SR 펠릿에 1mg/kg/BW 레트로졸(letrozole) 처치 후 자연회복군이 혼합된 실험군(PCOS+positive)에서는 혈중 황체형성호르몬/난포자극호르몬 비율(LH/FSH ratio)이 감소하였다는 것을 확인하였다(도 3).
(PCOS) mixed with 1 mg / kg / BW letrozole and 0.1 mg / kg / BW letrozole SR pellets and 1 mg / kg / BW letrozole and 0.1 mg / kg / and 500mg / kg / BW Ecklonia cava extract (Ecklonia cava) a mixed group (PCOS + EC500) and a total test period of 4 weeks, the first part 2 weeks 1mg / kg / BW letrozole (letrozole) administration, and 0.1mg / kg / (LH / FSH ratio) was determined using a natural recovery group (PCOS + positive) except for the administration of letrozole for 2 weeks in the second half of the study. As shown in FIG. 3, in the PCOS-induced group of 1 mg / kg / BW letrozole (PCOS), the luteinizing hormone / follicle stimulating hormone ratio (LH / FSH ratio) was statistically significantly increased , And the 500 mg / kg / BW tendency of the present invention ( Ecklonia cava) extracts the mixed group (PCOS + EC500) and 0.1mg / kg / BW letrozole (letrozole) after 1mg / kg / BW letrozole (letrozole) treatment in the SR pellets of natural recovery group a mixed group (PCOS + positive ) Showed a decrease in the ratio of luteinizing hormone / follicle stimulating hormone (LH / FSH ratio) (Fig. 3).
실시예Example 4. 4. 감태Moth 추출물의 혈중 난포자극호르몬(follicular stimulating hormone) 변화 확인 Identification of follicular stimulating hormone changes in the extract
동물모델을 이용하여, 혈중 난포자극호르몬(follicular stimulating hormone) 의 함량 변화를 확인하였다. PCOS 유도된 1mg/kg/BW 레트로졸(letrozole)의 투여군에서는 혈중 난포자극호르몬(follicular stimulating hormone)의 함량이 통계적으로 유의미하게 감소하였고, 본 발명의 500mg/kg/BW 감태(Ecklonia cava) 추출물이 혼합된 실험군(PCOS+EC500)과 0.1mg/kg/BW 레트로졸(letrozole) SR 펠릿에 1mg/kg/BW 레트로졸(letrozole) 처치 후 자연회복군이 혼합된 실험군(PCOS+positive)에서 혈중 난포자극호르몬(follicular stimulating hormone)이 증가하였다는 것을 확인하였다(도 4).
Using an animal model, changes in the content of follicular stimulating hormone were observed. The content of follicular stimulating hormone in the PCOS-induced group of 1 mg / kg / BW letrozole was statistically significantly decreased, and the extract of Ecklonia cava of 500 mg / kg / BW of the present invention (PCOS + EC500) and 0.1 mg / kg / BW letrozole SR pellets were treated with 1 mg / kg / BW letrozole, and the natural recovery group (PCOS + positive) It was confirmed that follicular stimulating hormone was increased (FIG. 4).
실시예Example 5. 혈중 테스토스테론( 5. Blood testosterone ( testosteronetestosterone ) 감소 효과) Reduction effect
동물모델을 이용하여, 혈중 테스토스테론(testosterone)의 함량 변화를 확인하였다. PCOS 유도된 1mg/kg/BW 레트로졸(letrozole)의 투여군(PCOS)에서는 혈중 테스토스테론(testosterone)의 함량이 통계적으로 유의미하게 증가하였고, 본 발명의 500mg/kg/BW 감태(Ecklonia cava) 추출물이 혼합된 실험군(PCOS+EC500)과 0.1mg/kg/BW 레트로졸(letrozole) SR 펠릿에 1mg/kg/BW 레트로졸(letrozole) 처치 후 자연회복군이 혼합된 실험군(PCOS+positive)에서 혈중 테스토스테론(testosterone)이 감소하였다는 것을 확인하였다(도 5).
Animal models were used to determine changes in serum testosterone content. PCOS induced 1mg / kg / BW letrozole (letrozole) administration group (PCOS) were in the content of serum testosterone (testosterone) increased statistically significant, 500mg / kg / BW Ecklonia cava of the present invention (the Ecklonia cava) extracts the mixed group (PCOS + EC500) and 0.1mg / kg / BW letrozole (letrozole) after 1mg / kg / BW letrozole (letrozole) treatment in the SR pellets of natural recovery group a mixed group (PCOS + positive ) Showed a decrease in blood testosterone (Fig. 5).
실시예Example 6. 난소 내 6. Ovary 난포낭I'm a cyst 수에 대한 효과 Effect on number
감태 추출물의 난소 내 난포낭 수에 대한 효과를 조사한 결과, 하기 표 1에 나타난 바와 같이, 레트로졸(letrozole) 단독(PCOS)과 비교하여 감태 추출물과 레트로졸(letrozole) 혼합물을 처리한 실험군(PCOS+EC500)의 난소 내 난포낭 수가 현저히 감소하는 것을 확인할 수 있었다.As shown in the following Table 1, the effects of the extracts of Ganoderma lucidum on the ovarian oocyst number were investigated in an experimental group (PCOS) treated with a mixture of Ganoderma lucidum extract and letrozole in comparison with letrozole alone (PCOS) + EC500) significantly decreased in ovarian cysts.
*P < 0.05 versus CON, # P < 0.05 versus PCOS* P < 0.05 versus CON, # P < 0.05 versus PCOS
Claims (8)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170048334A KR101907849B1 (en) | 2017-04-14 | 2017-04-14 | Composition for preventing, improving or treating disorder associated with polycystic ovary syndrome comprising extract of Ecklonia cava as effective component |
| PCT/KR2018/004237 WO2018190630A1 (en) | 2017-04-14 | 2018-04-11 | Composition for preventing, ameliorating or treating polycystic ovary syndrome-related diseases comprising ecklonia cava extract as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170048334A KR101907849B1 (en) | 2017-04-14 | 2017-04-14 | Composition for preventing, improving or treating disorder associated with polycystic ovary syndrome comprising extract of Ecklonia cava as effective component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101907849B1 true KR101907849B1 (en) | 2018-10-12 |
Family
ID=63792765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170048334A KR101907849B1 (en) | 2017-04-14 | 2017-04-14 | Composition for preventing, improving or treating disorder associated with polycystic ovary syndrome comprising extract of Ecklonia cava as effective component |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101907849B1 (en) |
| WO (1) | WO2018190630A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200069880A (en) | 2018-12-07 | 2020-06-17 | 동신대학교산학협력단 | Composition containing extract of mixture of kajime and red shell |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113827611B (en) * | 2021-11-16 | 2023-04-25 | 复旦大学附属妇产科医院 | Application of seaweed extract GV971 in preparation of medicine for treating polycystic ovary syndrome |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101613448B1 (en) * | 2011-08-31 | 2016-05-02 | 한국해양대학교 산학협력단 | n-Butanol substracts of Ecklonia cava for preventing obesity |
| KR20160094830A (en) * | 2015-01-30 | 2016-08-10 | 안용석 | Pharmaceutical composition comprising the fermentation extract of ecklonia cava as an effective component for prevention or treatment of thrombosis and health functional food comprising the same |
-
2017
- 2017-04-14 KR KR1020170048334A patent/KR101907849B1/en active IP Right Grant
-
2018
- 2018-04-11 WO PCT/KR2018/004237 patent/WO2018190630A1/en active Application Filing
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200069880A (en) | 2018-12-07 | 2020-06-17 | 동신대학교산학협력단 | Composition containing extract of mixture of kajime and red shell |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018190630A1 (en) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070134353A1 (en) | Phytoestrogenic composition comprising an extract of chinese licorice root, isoliquiritin or liquiritin | |
| US20100316741A1 (en) | Composition comprising the extract of crude drug complex for stimulating bone growth | |
| US10342836B2 (en) | Composition having a function for alleviating premenstrual syndrome and menstrual pain | |
| US20120076874A1 (en) | Composition with improved bioavailability of saponin and method for improving the bioavailability of saponin (as amended) | |
| EP1618875B1 (en) | Composition for inhibition or prevention of bone density lowering | |
| KR101907849B1 (en) | Composition for preventing, improving or treating disorder associated with polycystic ovary syndrome comprising extract of Ecklonia cava as effective component | |
| KR101931226B1 (en) | Composition for preventing, alleviating or treating disorder associated with polycystic ovary syndrome comprising extract of Cassiae Semen as effective component | |
| TW201636037A (en) | Composition comprising ginseng berry extracts for improved ovarian aging | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| KR101263451B1 (en) | Composition for preventing and treating of neuropathic pain containing ginsenoside Rb１ and Rg３，Compound K，or saponin extract from Panax ginseng as an effective ingredient | |
| KR20170076560A (en) | A herbal mixtuer extract with improved implantation and use thereof | |
| KR101732483B1 (en) | Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component | |
| KR102122408B1 (en) | Composition for preventing, ameliorating or treating andropause syndrome comprising roasted Glycyrrhiza uralensis extract as effective component | |
| KR102362480B1 (en) | Composition for preventing, ameliorating or treating androgens syndrome comprising Scintilla Barbara extract as effective component | |
| KR101585607B1 (en) | The Pharmaceutical composition for prevention or treatment of female infertility containing Rehmannia glutinosa Liboschitz var.purpurae Makino, Lycium chinense Miller, Aquillaria agallocha Roxburgh, Poria cocos Wolf, Panax ginseng C.A. Meyer and honey as a active ingredient | |
| KR101874458B1 (en) | Composition for preventing, improving or treating disorder associated with polycystic ovary syndrome comprising extract of Tetragonia tetragonoides as effective component | |
| KR102070793B1 (en) | Composition for preventing, alleviating or treating ovarian dysfunction comprising Allium fistulosum extract as effective component | |
| KR20220147238A (en) | Composition for prevention, treatment or improvement of metabolic syndrome-related diseases comprising Soybean cultivar Cheongja5ho | |
| KR101420270B1 (en) | Composition comprising reacted mixture of red ginseng extract and persimmon vinegar for preventing or treating benign prostatic hyperplasia | |
| KR101874460B1 (en) | Composition for preventing, improving or treating depression caused by estrogen secretion decrease comprising Tetragonia tetragonoides extract as effective component | |
| KR20210003523A (en) | Composition for preventing, ameliorating or treating andropause syndrome comprising Lycium chinense extract as effective component | |
| KR20050003665A (en) | Composition comprising an extract of Peucedanum japonicum for preventing and treating diabetes | |
| KR102354292B1 (en) | Composition for preventing, ameliorating or treating andropause syndrome comprising Vitex rotundifolia extract as effective component | |
| KR20190043920A (en) | Composition for preventing, alleviating or treating disorder associated with polycystic ovary syndrome comprising extract of Glycyrrhizae Radix et Rhizoma as effective component | |
| KR20130025926A (en) | Composition for preventing and treating of neuropathic pain containing ginsenoside Rb1 and Rg3,Compound K,or saponin extract from Panax ginseng as an effective ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GRNT | Written decision to grant |